A Prospective, Open Label, Randomised, Comparative, Crossover Clinical Study to Evaluate the Taste and Sensation Effects of Nimorazole 200mg mouth dissolving tablet (F4 formulation) and NimoralÂ® 500mg tablet manufactured for DeVats (India) Private Limited, New Delhi in Clinically Healthy Adults.

DeVats India Private Limited0 个研究点目标入组 6 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Clinically healthy adults between the ages of 18 and 50 (both sexes)
•2.Subject who understand and willing to sign informed consent document before start of any study specific assessment.
•3.Subject has not participated in a similar investigation in the past four weeks.

•1.Subject who have known history of misplaced taste perceptions
•2.Subjects who are smokers or have quit smoking within the last 6 months.
•3.Subjects who are currently having or recently has upper respiratory or middle ear infections
•4.Subjects who have recently undergone chemotherapy/ radiation treatment for head and neck cancers.
•5.Subjects with recent surgeries to the ear, nose, throat including wisdom tooth extraction in the past 4 weeks.
•6.Subjects with Olfactory disorders such as anosmia, partial anosmia, hyposmia, hyperosmia, dysosmia, phantosmia, olfactory agnosia.
•7.Subjects with poor oral hygiene, mouth ulcers or other dental problems such as gingival or periodontal infections.
•8.Subjects with history of thyroid imbalances.
•9.Subjects who are on treatment with DMARD, anti inflammatory drugs, immunosuppresents for the past 6 months before inclusion into the trial.
•10.Subjects who are planning a pregnancy, reported pregnant or lactating.
•11.Subjects, who in the opinion of the Investigator are not eligible for enrollment in the study.

发起方

DeVats India Private Limited